NCT03890770View on ClinicalTrials.gov

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

February 7, 2020

Study Completion Date

February 13, 2020

Conditions
Renal ImpairmentHealthy Volunteer
Interventions
DRUG

BMS-986165

Oral administration

Trial Locations (6)

1115

Szent Imre Egyetemi Oktatokorhaz, Budapest

4043

Kenezy Gyula Korhaz es Rendelointezet, Debrecen

32809

Orlando Clinical Research Center, Orlando

170 00

Pharmaceutical Research Associates CZ, s.r.o, Prague

05-825

Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II, Grodzisk Mazowiecki

31-559

Specjalistyczne Centrum Medyczne Chirurgii Maloinwazyjnej SCM, Krakow

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03890770 - A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease. | Biotech Hunter | Biotech Hunter